#HVO hVIVO PLC – Interim results September 12, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its unaudited interim results for the six-month period ended 30 June 2023.   Financial highlights ·    First half revenue growth of 52% to £27.3 million* (H1 2022: £18.0 million) ·    EBITDA more than doubled to £5.2 million (H1 2022: £2.3 million) ·    EBITDA margin increased to 19.1% (H1 2022: 12.6%) ·    Net cash…

Continue reading